Kornimate/medical-research-clean huggingface dataset:
preoperative prediction of of thymic epithelial tumors by diffusion-weighted mr imaging

Conditions: Thymic Epithelial Tumor

Summary: the aim of this study is to analyze aquaporins expression of thymic epithelial tumors and to compare them with apparent diffusion coefficient(adc) from ultra-high b-values, and to test a possibility of use of adcuh to identify the pathological type of tumor.

magnetic resonance (mr) diffusion-weighted imaging (dwi) measures water diffusion in biological tissue. the quantification of diffusion is described by the apparent diffusion coefficient (adc),which largely depends on the number and separation of barriers.thus, adc can provide information regarding tissue microstructure. according to the literature, adc is also related to cell membrane permeability for water molecules.it is well known that cellular water transport depends on aquaporins (aqps).in general,the expression of aquaporins might differ in several pathologic disorders. with reference to this fact,we hypothesize that aqps expression may influence adc in thymic epithelial tumors(tets).therefore,the aim of the present study is to analyze possible associations between adc from ultra-high b-values and aqps expression(adcuh) in tets and to use adcuh to identify the pathological type of tumor.

Eligibility criteria:
inclusion criteria: * no use of corticosteroid drugs; * no mri contraindication; * no infection or fever; * tumor diameter is greater than 2cm. exclusion criteria: -

Keywords: apparent diffusion coefficient aquaporins
computer guided contouring of craniofacial fibrous dysplasia involving zygoma

Conditions: Craniofacial Fibrous Dysplasia

Summary: this study will be conducted on patients with monostotic unilateral craniofacial fibrous dysplasia affecting zone i (fronto-orbital, zygomatic, and upper maxillary regions). computer guided shaving will be performed for all the patients, and the accuracy of this procedure will be assessed.

this study will be conducted on patients with monostotic unilateral craniofacial fibrous dysplasia affecting zone i (fronto-orbital, zygomatic, and upper maxillary regions). i. preoperative preparation 1. virtual planning computed tomography (ct) will be performed for the skull using a multi-slice helical ct machine. computed tomography dicom (digital imaging and communication in medicine) files will be imported to the 3d surgical planning software (mimics 10.0, materialise nv, leuven, belgium). using the software and through a series of segmentation and simulation processes, area of interest will be virtually selected and separated. finally, the virtual image of the surgical guide will be reconstructed. 2. rapid prototyping stereolithographic (stl) files of the virtual image will be exported to multi-jet modelling printing machine (invision si2, 3d systems e rock hill, sc) and will be fabricated using plastic material (visijet sr 200, 3d systems e rock hill, sc). ii. surgical procedures area of interest for all patients will be exposed using the hemicoronal, and maxillary intraoral vestibular incisions. the surgical guide(s) will be seated in position on the affected side. bone removal will be performed through the guide according to the preoperative planning. the bone removal will be then performed to connect the guiding holes using surgical burs. finally, the incisions will be sutured after soft tissue suspension. iii. follow up postoperative ct will be performed for postoperative assessment. after 1 week patients will be recalled for suture removal and clinical assessment. then the patients will be recalled 1, 3 months for further assessment.

Eligibility criteria:
inclusion criteria: * monostotic unilateral craniofacial fibrous dysplasia. * facial asymmetry affecting zone i (fronto-orbital, zygomatic, and upper maxillary regions) * more than 17 years exclusion criteria: * functional deficits * orbital manifestations
a phase i clinical trial evaluating the safety, tolerability, and pharmacokinetics of cu-40101 liniment in single and multiple doses in adult male androgenic alopecia subjects

Conditions: AGA

Summary: 1. to evaluate the safety and tolerability of cu-40101 liniment as a single and multiple topical application in adult male androgenic alopecia subjects； 2. to evaluate the pharmacokinetic (pk) characteristics of cu-40101 liniment administered as a single and multiple topical skin application in adult male subjects with androgenic alopecia.


Eligibility criteria:
inclusion criteria: 1. subject has provided written informaed consent. 2. subject is male, 18-55 years old. 3. subject has a clinical diagnosis of moderate to severe aga in temple and vertex region, ⅲ to ⅶ on the modified norwood-hamilton scale. 4. subject has a body mass index(bmi) of 19 to 28 kg/㎡ inclusive and body weight not less than 50kg. 5. according to the history, physical examination, vital signs, 12-lead electrocardiogram and laboratory examination results, the patient was in good health with no clinically significant abnormalities 6. subjects (including partners) are willing to take effective contraceptive measures voluntarily within 3 months from signing the informed consent to the last dose. exclusion criteria: 1. allergic to the study drug or any ingredient in the study drug 2. skin damage or abnormality at the administration site may affect drug absorption or evaluation, such as dermatitis, scar, tattoo, sunburn, etc 3. subjects who currently have thyroid disease (including hyperthyroidism, hypothyroidism, etc.) or are currently receiving thyroxine replacement therapy. thyroid function abnormalities on blood tests at the screening stage or thyroid ultrasound that the investigator judged to be clinically significant must be excluded 4. any surgical procedures performed within 3 months prior to screening, or planned during the study and within 1 month after the subject completed all study visits 5. a history of clinically significant heart, liver, neurological, respiratory, hematological, digestive, immune, renal, or psychiatric disorders that the investigator believes may confound study results or affect drug absorption, distribution, metabolism, and excretion or place the subject at inappropriate risk
all on four versus all on three implant treatment concepts

Conditions: Prosthesis Durability

Summary: the evaluation of patient satisfaction of all on-4 versus all on-3 implant treatment concepts rehabilitation of atrophied mandibular ridge.

patients will be classified into 2 groups according to the implant treatment concept they received: * group 1 (control group); included patients who received all on 4 implant-supported fixed restoration. the patients received 2 inclined implants anterior to the mental foramina and 2 vertical implants in the lateral incisor/canine areas. * group 2 (test group); included patients who received all on 3 implant-supported fixed restoration. the patients received 2 inclined implants anterior to the mental foramina and 1 vertical implant in the midline of the mandible.

Eligibility criteria:
inclusion criteria: * 1. all patients already have implants inserted in their mandibular ridges according to the all on 4 or all on 3 concepts. 2. they were healthy, free from any systemic diseases relating to bone resorption such as uncontrolled diabetes or osteoporosis. this was achieved through medical history and clinical examination by the physician. 3. all patients have sufficient inter-arch space. 4. all patients are of angle class i maxillo-mandibular relationships. 5. all patients had maxillary conventional complete dentures. exclusion criteria: 1. any neuromuscular disorders 2. uncooperative patients -
mechanism of cardiac and cerebral function injury caused by intraoperative limb ischemia-reperfusion

Conditions: Ischemic Reperfusion Injury

Summary: as a simple auxiliary tool for lower extremity orthopedic surgery, tourniquet can effectively reduce intraoperative bleeding and ensure the clarity of the operative field, effectively shorten the operation time and improve the operation efficiency. the extensive use of tourniquets in lower extremity surgery will not only cause local paralysis, pain and other complications, but also bring about postoperative complications such as large drainage volume and deep vein thrombosis. recent studies have found that tourniquet induced ischemia-reperfusion injury not only affects the local tissue structure and function of skeletal muscle, but also causes reperfusion injury in distant organs (such as heart, lung and brain). therefore, improving tourniquet ischemia-reperfusion injury after knee replacement is of great significance to improve the quality of life of patients during the perioperative period. therefore, the aim of this study was to investigate the effects of dexmedetomidine and tourniquet pretreatment on myocardial injury and brain injury caused by lower extremity ischemia-reperfusion.


Eligibility criteria:
inclusion criteria: * patients undergoing tka under general anesthesia * voluntarily sign the informed consent * asa grade i to iii * bmi 18-28 kg/m2 exclusion criteria: * congenital heart disease or history of cardiac surgery, heart conduction disease, frequent ventricular/atrial premature beats, atrial fibrillation and other serious arrhythmias * severe liver disease and kidney disease * temporary and permanent pacemaker implantation * patients with serious central nervous system diseases or serious mental disorders * recent history of sedation, antidepressant or opioid use * body mass index \>35kg/m2 * participants in other clinical trials within 1 month prior to study enrollment.
a pilot study to explore the use of skin biopsy as diagnostic tool in anterior cutaneous nerve entrapment syndrome (acnes)

Conditions: Anterior Cutaneous Nerve Entrapment Syndrome; Nerve Entrapment Syndrome; Chronic Pain Syndrome; Diagnosis

Summary: acnes is a neuropathic pain condition of the abdominal wall. it is a clinical diagnosis based on patient's history and physical examination. no diagnostic test is available to confirm the diagnosis. this pilot study will determine if skin biopsies can be used as diagnostic test. two 3mm biopsies will be taken and used to count the small nerve fibres in the skin. the number of small nerve fibres of the painful skin will be compared to non-painful skin. skin biopsy and small fibre nerve count is already used as diagnostic test in patients with small-fibre neuropathy. the investigators hypothesize that patients with acnes will have a reduced number of small nerve fibres in the affected skin, compared to the non-affected skin.


Eligibility criteria:
inclusion criteria: * duration of pain \>3 months * newly diagnosed unilateral acnes * fully completed intake questionnaire * obtained written informed consent exclusion criteria: * inability to understand dutch language * bilateral acnes * previously administered injections with corticosteroids at trigger point (injection with a local anaesthetic is allowed) * previous pulsed radiofrequency (prf)-treatment at trigger point * history of open abdominal surgery * history of neurectomy * known neuromuscular or neurodegenerative disease * antiplatelet or anticoagulants use or known coagulation disorders * disorder known to cause a reduced ienfd; * diabetes * hypothyroidism * renal failure * vitamin b12 deficiency * monoclonal gammopathy * alcohol abuse (\>5 iu a day) * malignancies * medication that cause neuropathy (for example chemotherapy)

Keywords: diagnostic test for acnes intraepidermal nerve fibre density (ienfd)
safety, tolerability and efficacy of actimmune® dose escalation in friedreich's ataxia

Conditions: Friedreich's Ataxia

Summary: the purpose of this phase 3 randomized, multi-center, double-blind, placebo-controlled study is to evaluate the efficacy and safety of actimmune® (interferon-γ 1b) in the treatment of friedreich's ataxia (fa) and to evaluate the pharmacokinetic (pk) characteristics of actimmune® in fa patients.

study with completed results acquired from horizon in 2024.

Eligibility criteria:
inclusion criteria: * written informed consent and child assent, if applicable. * fa confirmed by genetic testing with two expanded guanine-adenine-adenine (gaa) repeats. * fa functional stage of \>1 to \<5 and ability to walk 25 feet with or without an assistive device. * male or female subject between the ages of 10 and 25 years, inclusive. * if female, the subject is not pregnant or lactating or intending to become pregnant during the study, or within 30 days after the last dose of study drug. female subjects of child-bearing potential must have a negative serum pregnancy test result at screening, a negative urine pregnancy test result at baseline, and agree to use a reliable method of contraception throughout the study and for 30 days after the last dose of study drug. exclusion criteria: * any unstable illness that in the investigator's opinion precludes participation in the study. * use of any investigational product within 30 days prior to randomization. * a history of substance abuse. * presence of clinically significant cardiac disease (as determined by the investigator based on electrocardiogram \[ecg\] and echocardiogram results at screening). specifically, an ejection fraction of \ 50% of cycle duration) will result in exclusion. if the investigator notes any other clinically significant abnormalities on the ecg or echocardiogram, the subject may be eligible if they are provided clearance from a cardiologist. * history of hypersensitivity to interferon (ifn)-ɣ or e. coli-derived products. * presence of moderate or severe renal disease (estimated creatinine clearance \ 2x the upper limit of normal) as evidenced by laboratory results at screening. * clinically significant abnormal white blood cell count, hemoglobin, or platelet count as evidenced by laboratory test results at screening.

Keywords: interferon gamma
stimulation galvanique vestibulaire

Conditions: Hypertensive Hemorrhage of Right Parietal Lobe

Summary: right posterior parietal cortex is involved in spatial cognition. blindfolded patients suffering right posterior parietal lesions fail to update their own position after a body rotation. right cathodal galvanic vestibular stimulation activates right posterior parietal cortex and reduces symptoms of spatial neglect, another disability frequently encountered after right posterior parietal lesion. the aims of this study are to confirm posterior parietal involvement in automatic updating of body-centered spatial relationships and to evaluate therapeutic effects of galvanic vestibular stimulation. performances of three groups of adults are compared before and during galvanic vestibular stimulation on a pointing task: a healthy control group, a brain-injured control group with stroke lesions sparing right posterior parietal cortex and a group of stroke patients with right posterior parietal lesions.


Eligibility criteria:
inclusion criteria: * patient with right posterieur parietal lobe lesion * patient with cerebral vascular stroke * healthy volonteers age greater than or equal to 18 written informed consent exclusion criteria: * patient's refusal to participate to the study * inability to cooperate * cognitive trouble * epilepsy

Keywords: galvanic vestibular stimulation right parietal lobe lesion egocentric space
tai chi mind-body therapy for chronic heart failure

Conditions: Heart Failure

Summary: the purpose of this study is to determine the effects of a tai chi exercise program on functional capacity and health-related quality of life in patients with chronic heart failure (hf). this study will also examine the way tai chi influences mental, physical, and social functioning.

hf is a major public health problem in the united states, affecting approximately 5 million adults. despite recent advances in pharmacologic therapy and technologic devices, hf is the most common reason for hospitalization among medicare patients and is reaching epidemic proportions as the population ages. new and inexpensive interventions that can improve functional capacity and quality of life and can delay disease progression are needed. tai chi is a popular mind-body exercise that is a potential treatment for heart disease. this exercise incorporates both gentle physical activity and meditation, and it may be particularly suited to frail patients with hf. this study will examine the effects of a tailored tai chi program on functional capacity and quality of life in patients with hf. participants will be randomly assigned to either a tai chi program or heart health education for 12 weeks. participants in both groups will undergo a bicycle stress test at study entry and will receive weekly training sessions of their assigned intervention. self-report scales and questionnaires will be used to assess participants at study start and at the end of 12 weeks.

Eligibility criteria:
inclusion criteria: * diagnosis of chronic hf * percentage of blood pumped from the left ventricle (ventricular ejection fraction) less than 40% for at least 1 year prior to study entry * stable medical regimen, defined as no major changes in medication, in the 3 months prior to study entry * new york heart association classification of class i (no activity limitations), class ii (slight activity limitations), or class iii (marked activity limitations) * english-speaking exclusion criteria: * unstable angina, myocardial infarction, cardiac resynchronization, or major cardiac surgery within 3 months prior to study entry * history of cardiac arrest or diagnosis of peripartum cardiomyopathy within 6 months prior to study entry * unstable ventricular arrhythmias or structural valvular disease * current participation in a conventional cardiac rehabilitation program * inability to perform a bicycle stress test at study entry * lower extremity amputation or other inability to walk due to conditions other than hf * severe cognitive dysfunction preventing informed consent and understanding of tai chi concept * current regular practice of tai chi * current participation in a tai chi pilot study or other studies

Keywords: complementary therapies tai chi
a phase i/ii study to evaluate the safety and immunogenicity of gc3111b in healthy adults

Conditions: Tetanus-diphtheria-acellular Pertussis (Tdap)

Summary: this clinical trial consists of two parts: part 1, which explores safety, and part 2, which examines both safety and efficacy (immunogenicity). part 1 is a single-center, open-label, single-group study, while part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.


Eligibility criteria:
inclusion criteria: * healthy adults aged 19 to 64 years old as of the date of written consent. * individuals with no history of vaccination with a vaccine containing diphtheria, tetanus, or pertussis antigens within the past 2 years prior to administration of the investigational product. exclusion criteria: * individuals who have received a vaccine within 4 weeks prior to administration of the investigational product. * individuals with a history of tdap vaccination prior to administration of the investigational product. * pregnant and breastfeeding women. * individuals who have participated in other clinical trials involving investigational products/devices within 6 months prior to administration of the investigational product.
immunophenotyping of acute b cell lymphoblstic leukemia

Conditions: Acute Leukemia

Summary: to study the immunophenotyping pattern of acute b lymphoblastic leukemia in south egypt cancer institute iand its correlation with disease outcome

study the immunophenotyping pattern of acute b lymphoblastic leukemia in south egypt cancer institute from 2009 -2019 and its correlation with disease outcome

Eligibility criteria:
inclusion criteria: * new cases admitted to seci who didn't receive treatment.age above 1 years old. exclusion criteria: * cases who received treatment patients below 1 years old.patients diagnosed as aml or t-all
effectiveness and safety of bms-986165 compared to placebo and active comparator in participants with psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to investigate the experimental medication bms-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * plaque psoriasis for at least 6 months * moderate to severe disease * candidate for phototherapy or systemic therapy exclusion criteria: * other forms of psoriasis * history of recent infection * prior exposure to bms-986165 or active comparator other protocol defined inclusion/exclusion criteria apply
successful microsurgical breast reconstruction in minimally invasive mastectomy

Conditions: Breast Reconstruction; Breast Cancer

Summary: a retrospective chart review will be conducted to identify patients who received breast reconstruction surgery with diep flaps by a single plastic surgeon in one medical center between november 2018 and july 2022. patients will be grouped based on how the mastectomy was performed, via minimally invasive or conventional approach. demographic data, flap profile, vessel anastomosis and post-operative complication will be retrospectively reviewed. data collection includes patient demographics, previous breast surgical history, breast cancer history and adjuvant therapy, surgical details and postoperative events.


Eligibility criteria:
inclusion criteria: * patients who received nipple sparing mastectomy and breast reconstruction from november 2018 to july 2022 from a single breast reconstruction surgeon. exclusion criteria: * patients failed to be examined for outcome evaluation will be excluded from the study.

Keywords: free flap breast reconstruction minimally invasive mastectomy nipple-sparing mastectomy robotic-assisted mastectomy endoscopic-assisted mastectomy
comparing the outcome of cemented all-polyethylene pegged vs. keeled components through a subscapularis tenotomy or a subscapularis peel

Conditions: Arthropathy Shoulder; Shoulder Pain; Shoulder Osteoarthritis; Shoulder Arthritis; Shoulder Arthropathy Associated With Other Conditions; Necrosis of Bone; Arthritis; Inflammatory Arthritis

Summary: participants who choose to participate in this study, will either have their tendon repaired to tendon, so-called tenotomy repair, or tendon repaired to bone, so-called peel repair.


Eligibility criteria:
inclusion criteria: * subjects willing to sign the informed consent * male and female subjects ages 18 - 90 at the time of surgery * subjects indicated for an anatomic total shoulder arthroplasty (including primary glenohumeral osteoarthritis, avascular necrosis, and inflammatory arthritis) exclusion criteria: * inability to comply with follow-up requirements * known or presumed substantial rotator cuff disorders * subjects with an active or suspected latent infection in or about the shoulder * subjects with instability (surgically or non-surgically addressed) * subjects presenting with posttraumatic avascular necrosis * need for glenoid bone grafting * pregnant subjects